Profund Advisors LLC Has $1.61 Million Position in Roivant Sciences Ltd. $ROIV

Profund Advisors LLC cut its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 16.4% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 106,639 shares of the company’s stock after selling 20,902 shares during the period. Profund Advisors LLC’s holdings in Roivant Sciences were worth $1,613,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Goldman Sachs Group Inc. increased its position in shares of Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after acquiring an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Roivant Sciences by 1.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock valued at $24,678,000 after purchasing an additional 34,341 shares during the last quarter. KLP Kapitalforvaltning AS grew its stake in Roivant Sciences by 6.6% in the second quarter. KLP Kapitalforvaltning AS now owns 76,100 shares of the company’s stock valued at $858,000 after purchasing an additional 4,700 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its position in shares of Roivant Sciences by 28.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 43,612 shares of the company’s stock worth $492,000 after purchasing an additional 9,548 shares during the last quarter. Finally, CWM LLC raised its stake in shares of Roivant Sciences by 44.6% during the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after purchasing an additional 920 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Price Performance

NASDAQ:ROIV opened at $27.35 on Wednesday. The company has a market cap of $19.02 billion, a P/E ratio of -23.38 and a beta of 1.22. The firm’s fifty day moving average price is $22.36 and its two-hundred day moving average price is $18.08. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $27.94.

Insiders Place Their Bets

In other news, CFO Richard Pulik sold 406,731 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $22.43, for a total value of $9,122,976.33. Following the transaction, the chief financial officer owned 239,413 shares of the company’s stock, valued at approximately $5,370,033.59. This represents a 62.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Vivek Ramaswamy sold 1,975,858 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $21.96, for a total value of $43,389,841.68. Following the transaction, the insider owned 36,350,621 shares in the company, valued at approximately $798,259,637.16. This trade represents a 5.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 12,132,392 shares of company stock worth $262,349,645 in the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ROIV shares. Citigroup raised their target price on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday. HC Wainwright increased their price target on shares of Roivant Sciences from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $30.00 target price on shares of Roivant Sciences in a report on Monday. Finally, TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.69.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.